Table 5.
Next generation sequencing (NGS) analysis using tissue samples before and after afatinib or first‐generation EGFR‐TKI
| Before EGFR‐TKI | After EGFR‐TKI | Efficacy of osimertinib | |||||
|---|---|---|---|---|---|---|---|
| EGFR mutations | Other mutations | EGFR mutations | Other mutations | PFS (months) | DOT (months) | ||
| Afatinib (Group A) | Patient 1 | Exon 21 L858R (26.3) |
CTNNB1 exon 2 S37Y (12.6) PIK3CA exon 20 G1049R (22.0) |
Exon 21 L858R (18.1) Exon 20 T790M (28.4) |
CTNNB1 exon 2 S37Y (9.1) PIK3CA exon 20 G1049R (13.9) |
11.4 | 13.0+ |
| Patient 2 | Exon 19 deletion (20.8) |
CTNNB1 Exon 2 S37F (1.1) TP53 exon 6 R248Q (1.0) Exon 5 Q192* (44.4) |
Exon 19 deletion (1.6) Exon 20 T790M (1.0) |
TP53 Exon 5 Q192* (1.6) |
30.1+ | 30.1+ | |
| Patient 3 |
Exon 21 L858R (2.0) Exon 20 T790M (1.9) |
RET Exon 11 R635C (2.3) TP53 Exon 7 E298K (1.8) |
Exon 21 L858R (32.7) Exon 20 T790M (22.3) |
22.0+ | 22.0+ | ||
| Patient 4 | Exon 19 deletion (45.2) |
TP53 Exon 6 N239S (83.7) |
Exon 19 deletion (9.8) Exon 20 T790M (8.7) |
TP53 Exon 6 N239S (7.1) |
16.1+ | 16.1+ | |
| Patient 5 | No available sample | No available sample |
Exon 19 deletion (46.1) Exon 20 T790M (33.9) |
20.4+ | 20.4+ | ||
| First‐generation EGFR‐TKI (Group B) | Patient 6 | Exon 19 deletion (28.3) |
CTNNB1 exon 2 S45P (27.1) |
Exon 19 deletion (25.5) Exon 20 T790M (17.3) |
CTNNB1 exon 2 S45P (18.4) |
4.4 | 4.4 |
| Patient 7 | Exon 19 deletion (37.4) |
TP53 exon 6 N239D (46.8) |
Exon 19 deletion (88.8) Exon 20 T790M (8.2) |
TP53 exon 6 N239D (90.6) |
20.7+ | 20.7+ | |
| Patient 8 | Exon 19 deletion (18.7) |
Exon 19 deletion (26.8) Exon 20 T790M (21.2) |
CTNNB1 exon 2 D32N (27.7) PIK3CA exon 9 E542K (28.5) |
19.6 | 19.8+ | ||
| Patient 9 |
Exon 19 deletion (8.3) Exon 20 T790M (1.5) Exon 20 R776H (2.0) |
ALK exon 20 D1091N (1.8) TP53 exon 4 P152L (2.5) |
Exon 20 T790M (28.5) |
18.1+ | 18.1+ | ||
| Patient 10 | Exon 19 deletion (11.0) |
Exon 19 deletion (33.4) Exon 20 T790M (39.6) |
PIK3CA exon 9 Q546K (7.0) |
25.9 | 27.1 | ||
| Patient 11 | Exon 21 L858R (2.1) |
Exon 21 L858R (6.1) Exon 20 T790M (1.9) Exon 7 A289V (1.1) |
11.9 | 30.8+ | |||
| Patient 12 | Exon 19 deletion (23.1) |
Exon 19 deletion (7.4) Exon 20 T790M (2.2) |
15.3 | 15.7 | |||
| Patient 13 | Exon 19 deletion (56.2) |
Exon 19 deletion (62.3) exon20 T790M (52.9) |
2.2+ | 2.2+ | |||
| Patient 14 | Exon 19 deletion (33.6) |
TP53 exon 7 R282W (35.2) |
Exon 19 deletion (37.1) Exon 20 T790M (31.1) |
TP53 exon 7 R282W (11.2) |
1.7+ | 1.7+ | |
Parentheses indicate allele frequency, %.
DOT, duration of treatment; PFS, progression‐free survival.